Mumbai: The initial fear that many post-covid patients will later develop lung fibrosis quickly recede in the medical corridor.
Even the lungs of patients who suffer from severe covid and pneumonia, show signs of healing within three-six months, according to a study by a doctor from Mumbai Hospital.
“We found in the maximum number of patients, the function of the lungs continued to be better,” said the lead author of the study, Pulmonologist Dr.
Sumeet Singhania from Kokilaben Ambani Hospital, Andheri.
The initial findings of this study were recently published in the ‘Lung India Journal’.
The team began this research mainly because of mass neurosis among patients about Covid destroying their lungs.
“But we found the majority of these patients, at the end of three months, showing a very good increase in the lungs, both structurally and functionally,” said Dr.
Singhania.
Pulmonary function tests of each patient and CT scanning are carried out.
While this study only had results from 42 patients treated with antiviral remdesivir and steroids, the medical team had completed a study of more than 300 patients, some of them were followed for a year.
Most of the 42 patients were hospitalized having severe pneumonia.
The study also focuses on debates in the medical community about whether to start covid patients with severe lung involvement in anti-fibrotic drugs.
Anti-fibrotic agent is intended for patients with idiopathic pulmonary fibrosis to slow down the pulmonary grated tissue.
Dr.
Lancelot Pinto, which was attached to Hinduja Hindu Hospital in Mahim and was not connected with this study, told TI that the debit paper from many Covid patients would show that they were wearing anti-fibrotic drugs.
“The medicine is not necessary and I have not prescribed one Covid patient in the last 16 months,” he said.
Kokilaben hospital studies underlined the same thought process.
“Our study shows that not each and everyone claiming to be hospitalized for Covid infection needs to begin on anti-fibrotic drugs,” said Dr.
Singhania.
Anti-fibrotic drugs, with their own definitions, are intended to capture lung scars or damage.
“They can’t reverse scar tissue.
So where the proof helps covid patients with lung scars,” asked Dr Pinto.
Dr.
Singhania said that even in certain covid patients with significantly improved lung grated tissue during a certain period of time.
“This study revealed that pneumonia Covid did not induce progressive fibrotic lanes in the lungs, at least three months of follow-up,” said the study of Indian lungs.